| __timestamp | BeiGene, Ltd. | Halozyme Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 21862000 | 22732000 |
| Thursday, January 1, 2015 | 58250000 | 29245000 |
| Friday, January 1, 2016 | 98033000 | 33206000 |
| Sunday, January 1, 2017 | 273992000 | 31152000 |
| Monday, January 1, 2018 | 707710000 | 10136000 |
| Tuesday, January 1, 2019 | 998528000 | 45546000 |
| Wednesday, January 1, 2020 | 1365534000 | 43367000 |
| Friday, January 1, 2021 | 1624145000 | 81413000 |
| Saturday, January 1, 2022 | 1926983000 | 139304000 |
| Sunday, January 1, 2023 | 379920000 | 192361000 |
| Monday, January 1, 2024 | 159417000 |
Data in motion
In the ever-evolving landscape of biotechnology, understanding the financial dynamics of key players is crucial. BeiGene, Ltd. and Halozyme Therapeutics, Inc. have been at the forefront, with their cost of revenue revealing intriguing trends over the past decade. From 2014 to 2023, BeiGene's expenses surged by over 8,700%, peaking in 2022, before a notable decline in 2023. This reflects their aggressive expansion and investment in research and development. Meanwhile, Halozyme's costs remained relatively stable, with a modest increase of around 750% over the same period, indicating a more conservative growth strategy. These insights not only highlight the contrasting financial strategies of these companies but also provide a window into the broader biotech industry's economic landscape. As investors and stakeholders, understanding these trends is key to making informed decisions.
Novo Nordisk A/S vs Halozyme Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Trends: Bristol-Myers Squibb Company vs BeiGene, Ltd.
Cost of Revenue Trends: Vertex Pharmaceuticals Incorporated vs Halozyme Therapeutics, Inc.
BeiGene, Ltd. vs Intra-Cellular Therapies, Inc.: Efficiency in Cost of Revenue Explored
BeiGene, Ltd. vs Pharming Group N.V.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Bio-Techne Corporation vs Halozyme Therapeutics, Inc.
Cost Insights: Breaking Down Sarepta Therapeutics, Inc. and Halozyme Therapeutics, Inc.'s Expenses
Analyzing Cost of Revenue: Halozyme Therapeutics, Inc. and Pharming Group N.V.
Cost of Revenue Comparison: Halozyme Therapeutics, Inc. vs ACADIA Pharmaceuticals Inc.
Cost Insights: Breaking Down Halozyme Therapeutics, Inc. and Mesoblast Limited's Expenses
Halozyme Therapeutics, Inc. vs Galapagos NV: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Halozyme Therapeutics, Inc. vs MiMedx Group, Inc.